Qi-Ying Hu

USPTO Granted Patents = 32 (Patent Applications = 16)

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 13 (Patent Applications = 16)

Average Co-Inventor Count = 3.3

ph-index = 4

Forward Citations = 88(Granted Patents)

Location History:

Cambrdige, MA (US) (2015)
Cambridge, MA (US) (2013 - 2021)
Needham, MA (US) (2011 - 2024)

Company Filing History:

Decibel Therapeutics, Inc.

patents

2 out of 531

Glaxosmithkline Biologicals Sa

patents

Years Active: 2011-2025

Loading Chart...

32 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12409231 - Cycloalkyne derivatized saccharides (2025-09-09),

2. 11857567 - Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent (2024-01-02),

3. 11690870 - Methods of otoprotection against platinum-based antineoplastic agents (2023-07-04),

4. 11311400 - Methods for making conjugates from disulfide-containing proteins (2022-04-26),

5. 11135300 - Cycloalkyne derivatized saccharides (2021-10-05),

6. 11071751 - Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent (2021-07-27),

7. 10813947 - Methods of otoprotection against platinum-based antineoplastic agents (2020-10-27),

8. 10709732 - Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent (2020-07-14),

9. 10667935 - Methods for making conjugates from disulfide-containing proteins (2020-06-02),

10. 10406198 - Methods for making conjugates from disulfide-containing proteins (2019-09-10),

11. 10172948 - Methods for oxime conjugation to ketone-modified polypeptides (2019-01-08),

12. 10022256 - Methods for making conjugates from disulfide-containing proteins (2018-07-17),

13. 9982017 - Synthetic apelin mimetics for the treatment of heart failure (2018-05-29),

14. 9434754 - Use of an adrenal hormone-modifying agent (2016-09-06),

15. 9278969 - Organic compounds (2016-03-08),

Title: Innovations and Contributions of Qi-Ying Hu in Pharmaceutical Patents

Introduction

Qi-Ying Hu, based in Needham, MA, has made significant strides in the field of pharmaceutical innovations, holding a remarkable total of 31 patents. His work focuses on developing novel methods and compositions aimed at improving patient outcomes during chemotherapy treatments, particularly regarding the use of platinum-based antineoplastic agents.

Latest Patents

Among his latest contributions are two noteworthy patents. The first patent outlines hypertonic pharmaceutical compositions that contain an anti-platinum chemoprotectant agent and a gelling agent. This innovative composition aims to provide protective benefits to patients undergoing treatments with platinum compounds. The second patent presents methods of otoprotection, detailing the administration of a thiosulfate salt to protect against the ototoxic effects of platinum-based antineoplastic agents. This method specifies important timelines for administration, ensuring maximum efficacy and safety for patients.

Career Highlights

Qi-Ying Hu has had a fruitful career with significant roles at esteemed organizations, including Novartis AG and Decibel Therapeutics, Inc. His experience in these prominent companies has provided him with the expertise required to innovate in the biopharmaceutical sector.

Collaborations

Throughout his career, Qi-Ying has collaborated with notable professionals such as Julien Papillon and Hidetomo Imase. These partnerships illustrate his ability to work with talented individuals in the scientific community to advance his research and patent applications.

Conclusion

In conclusion, Qi-Ying Hu's contributions to the field of pharmaceuticals through his patents illustrate his profound impact on improving cancer treatments and protecting patients from adverse effects. His dedication to innovation continues to pave the way for advancements in therapeutic options for those undergoing chemotherapy.

This text is generated by artificial intelligence and may not be accurate.